This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
I started my journey in chemistry – first as an undergraduate and then in my PhD programme at the University of Houston, where I focused on organicchemistry and nucleic acids chemistry. I originally wanted to be a doctor but that’s a second-tier track in France. I’m a CEO with a background in chemistry.
Elmaleh’s research has yielded compounds with potential in oncology, heart disease and neurodegenerative conditions, BOSTON, MA, October 23, 2020 /24-7PressRelease/ — Marquis Who’s Who, the world’s premier publisher of biographical profiles, is proud to honor David.
Inspired by a lifelong passion for nature and a fascination with the potential to address disease using naturally derived compounds, he earned a Bachelor of Science in chemical technology at Iowa State University of Science and Technology in 1961.
She is currently a Senior drug discovery scientist working across Cell Engineering, Cell Biology and Functional Genomics teams, using CRISPR/Cas9 and Next Generation Sequencing for target identification, target validation and drug development in the oncology disease area.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content